Describing the post (screenshot below) put up this morning as a teaser for the leak on Indoco, the gang said the company was mainly involved in the manufacture and marketing of formulations and active pharmaceutical ingredients.
On its website, Indoco describes itself as a "fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (Finished Dosage Forms) and active pharmaceutical ingredients (APIs)".
"We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a US$145 million company, employs about 6000 personnel, including over 300 skilled scientists," it adds. Indoco has a a state-of-the-art R&D centre at Rabale in Navi Mumbai and a clinical research organisation in Hyderabad.
Screenshot of the Nefilim announcement. Supplied
Its domestic marketing divisions include INDOCO, SPADE, Warren NxGen, Warren Ace, Spera, Indoco Focus, Indoco CND, Warren Excel, Warren Vision, Eterna, Institution and Indoco IMPULSE. The company’s products include Sensodent-K, Homide, Carmicide, Renolen, Rexidin M, Febrex Plus, Zincoren, Otorex, Cloben G, Methycal, Tuspel, Scabex, Hemsyl, Karvol Plus, Durashape, Lignox, Sensoform Toothpaste, Kidodent Toothpaste, Rosuchek D, Otichek and Irimist.
The Nefilim ransomware was in the news when a gang used it to attack Australian logistics and transport provider Toll Holdings in May.
The same ransomware was used to attack appliance maker Fisher & Paykel last month.
Nefilim, is one of the growing number of ransomware packages that encrypts data on-site while PowwerShell scripts are used to exfiltrate victims' files. This, in effect, means that any victim is hit by both a data breach and also loses access to his/her files.
iTWire has contacted Indoco for comment.